Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011

SAN DIEGO, Aug. 31, 2011 /PRNewswire/ — Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences:

               Stifel Nicolaus 2011 Healthcare
    --         Conference
              Date:     Wednesday, September 7, 2011
                         1:30pm Eastern Time (10:30am
              Time:      Pacific Time)
              Place:    Four Seasons Hotel in Boston
                         Scott Byrd, SVP & Chief
              Speaker:   Commercial Officer

          --  UBS Global Life Sciences Conference
              Date:     Tuesday, September 20, 2011
                         11:30am Eastern Time (8:30am
              Time:      Pacific Time)
                         Grand Hyatt Hotel in New
              Place:     York City
                         Ted Schroeder, President &
              Speaker:   CEO

          --  JMP Securities Healthcare Conference
                         Wednesday, September 28,
              Date:      2011
                         9:30am Eastern Time (6:30am
              Time:      Pacific Time)
                         The St. Regis Hotel in New
              Place:     York City
                         Ted Schroeder, President &
              Speaker:   CEO

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals’ website at www.cadencepharm.com on the Investor Relations page. A replay of each webcast will available approximately three hours after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. For more information about Cadence, visit www.cadencepharm.com.

    Contacts:   William R. LaRue
                SVP, CFO
                Cadence Pharmaceuticals, Inc.
                858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.